Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Hyoscine Butylbromide→

Hyoscine Butylbromide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
149-64-4
Molecular formula
C21H30BrNO4
Molecular weight
440.37 g/mol
Drug class
Peripheral antimuscarinic antispasmodicquaternary ammonium hyoscine derivative
Mechanism of action
Blocks muscarinic acetylcholine receptors in gastrointestinal, biliary and genitourinary smooth muscle and also has ganglion-blocking activity within the visceral wall. Its quaternary ammonium structure limits entry into the central nervous system.
Indications / reported uses
  • Relief of gastrointestinal and genitourinary smooth-muscle spasm
  • Symptomatic relief of irritable bowel syndrome
  • Injection products are used for acute spasm such as renal or biliary colic and during selected diagnostic procedures; indication depends on formulation

Sources: UK SmPC — Hyoscine butylbromide 10 mg · UK SmPC — Hyoscine butylbromide 20 mg · UK SmPC — Hyoscine butylbromide injection · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Hyoscine Butylbromide Environmental Risk Assessment (ERA) (the Hyoscine Butylbromide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.